Table 1. Correlation between PSMA3-AS1 expression and clinicopathological characteristics of CCA patients.
Clinicopathological parameters | Total | PSMA3-AS1 expression | P-value | |
Low | High | |||
Age (years) | ||||
<60 | 19 | 11 | 8 | 0.106 |
≥60 | 47 | 17 | 30 | |
Gender | ||||
Male | 29 | 14 | 15 | 0.394 |
Female | 37 | 14 | 23 | |
Differentiation grade | ||||
Well/moderate | 28 | 15 | 13 | 0.116 |
Poor/undifferentiated | 38 | 13 | 25 | |
Serum CA19-9 level | ||||
≤37 U/ml | 25 | 13 | 12 | 0.219 |
>37 U/ml | 41 | 15 | 26 | |
Serum CEA level | ||||
≤5 ng/ml | 23 | 13 | 10 | 0.090 |
>5 ng/ml | 43 | 15 | 28 | |
TNM stage | ||||
I–II | 20 | 13 | 7 | 0.014* |
III–IV | 46 | 15 | 31 | |
Lymph node invasion | ||||
No | 27 | 16 | 11 | 0.021* |
Yes | 39 | 12 | 27 |
*P < 0.05. Abbreviations: PSMA3-AS1: proteasome subunit α3 antisense RNA 1; CCA: cholangiocarcinoma; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen.